Pfizer Market Cap 2010-2022 | PFE

Pfizer market cap history and chart from 2010 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of March 24, 2023 is $225.83B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $225.833B $100.330B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $393.377B 14.87
Novo Nordisk (NVO) Denmark $331.955B 42.27
Eli Lilly (LLY) United States $314.520B 41.68
AbbVie (ABBV) United States $271.096B 11.03
Merck (MRK) United States $265.029B 13.96
Novartis AG (NVS) Switzerland $181.345B 13.41